FDA will not act on European study of GLP-1 drugs
The European Medicines Agency announced last week that it will investigate GLP-1 drugs for suicide risk. The US counterpart is not planning to follow suit.
by MARKETWIRE
Last week, the European Medicines Agency, EMA, announced that it will investigate GLP-1 receptor agonists, including Novo Nordisk’s Ozempic (semaglutide), Saxenda (liraglutide) and Wegovy (semaglutide) for suicide risk after several so-called safety signals were reported.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
